The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s biosimilar from the U.S. Two investigational eye therapies, from Opthea Limited and ...

Opthea and Uni­ty Biotech­nol­o­gy, which are both de­vel­op­ing new drugs for eye dis­eases, were un­able to beat or match afliber­cept, the stan­dard-of-care treat­ment that Re­gen ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary endpoint and the only time stamp out of 10 in which the candidate ...

Now, the candidate has failed to match Eylea in a phase 3 trial, leaving the Australian biotech to consider its own future. The drug in question is sozinibercept, an inhibitor of vascular ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently established that Amgen’s biosimilar Pavblu violates key patents of Eylea. A U.S.

The US Court of Ap­peals for the Fed­er­al Cir­cuit on Fri­day ruled against Re­gen­eron in a close­ly-watched patent in­fringe­ment case in­volv­ing the New York biotech’ … ...

At the heart of the controversy is Regeneron's alleged practice of paying credit card fees to distributors, on the condition that these fees were not passed on to Eylea customers. This ...

Approval for Eylea for diabetic retinopathy was based on six-month and one-year trial results from PANORAMA, a phase 3 trial that enrolled 402 patients comparing the drug with placebo.

Background: To identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting ...